Hypertrophic Cardiomyopathy Therapeutics Market Report 2024 (Global Edition)

Global Hypertrophic Cardiomyopathy Therapeutics Market Report 2024 Market Size Split by Disease Type Outlook: (Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy), by...

Hypertrophic Cardiomyopathy Therapeutics Market Report Description

We have various report editions of Hypertrophic Cardiomyopathy Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Hypertrophic Cardiomyopathy Therapeutics Market Insights Video

Competitive Landscape of the Hypertrophic Cardiomyopathy Therapeutics Market

The competitive landscape of the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market is shaped by a mix of established pharmaceutical companies, biotechnology firms, and emerging players focused on developing innovative treatments for this genetic disorder. The market is highly dynamic, driven by advancements in precision medicine, gene therapies, and novel drug formulations.

In February 2022, Cytokinetics, Incorporated opened enrollment for SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). (Source: https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-presents-new-data-relating-aficamten-and) In April 2022, Bristol Myers received approval from Food and Drug Administration (FDA) for its Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. (Source: https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-Camzyos-mavacamten-for-the-Treatment-of-Adults-With-Symptomatic-New-York-Heart)

Top Companies Market Share in Hypertrophic Cardiomyopathy Therapeutics Industry: (In no particular order of Rank)

• Astra Zeneca Plc
• ADVANZ PHARMA Corp (Concordia Healthcare Corp)
• Bayer AG
• Gilead Sciences
• Inc
• Merck & Co.
• Inc
• Mylan N.V.
• Novartis AG
• Pfizer
• Inc
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Hypertrophic Cardiomyopathy Therapeutics Market

Which Region Dominates the Hypertrophic Cardiomyopathy Therapeutics Market in 2024?

According to Cognitive Market Research, North America dominates the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market due to its advanced healthcare infrastructure, widespread access to cutting-edge diagnostic tools, and a high prevalence of cardiovascular diseases. The region has a robust ecosystem for research and development, supported by significant investment from pharmaceutical companies and government organizations. High awareness among healthcare providers and patients about the benefits of early diagnosis and targeted therapies further drives market growth.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is the fastest-growing region in the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market due to increasing awareness of cardiovascular diseases and improving healthcare infrastructure across emerging economies. Rapid advancements in diagnostic capabilities, including genetic testing and advanced imaging, have enhanced early detection rates in the region.

The current report Scope analyzes Hypertrophic Cardiomyopathy Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Hypertrophic Cardiomyopathy Therapeutics

According to Cognitive Market Research, the global Hypertrophic Cardiomyopathy Therapeutics market size was estimated at USD 1524.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 609.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Hypertrophic Cardiomyopathy Therapeutics market with a market size of USD 481.13million in 2024 and is projected to grow at a CAGR of 2.0%during the forecast period. The U.S. market's advanced healthcare infrastructure, increased awareness, and rising adoption of novel therapies.
• The Canada Hypertrophic Cardiomyopathy Therapeutics market had a market share of USD 73.18million in 2024 and is projected to grow at a CAGR of 3.0%during the forecast period. Canada’s advanced healthcare infrastructure, increased awareness, and rising adoption of novel therapies.
• The Mexico Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 2.7%during the forecast period, with a market size of USD 55.49million in 2024.

Europe Hypertrophic Cardiomyopathy Therapeutics

According to Cognitive Market Research, the global Hypertrophic Cardiomyopathy Therapeutics market size was estimated at USD 1524.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 457.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.5% from 2024 to 2031.

• The United Kingdom Hypertrophic Cardiomyopathy Therapeutics market had a market share of USD 76.83million in 2024 and is projected to grow at a CAGR of 3.3%during the forecast period. In the UK, Hypertrophic Cardiomyopathy Therapeutics sales witness an upswing due to the aging population and an increasing prevalence of cardiovascular diseases.
• The France Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 1.7%during the forecast period, with a market size of USD 42.08million in 2024.
• According to Cognitive Market Research, the German Hypertrophic Cardiomyopathy Therapeutics market size was valued at USD 90.56million in 2024 and is projected to grow at a CAGR of 2.7%during the forecast period. In Germany, Hypertrophic Cardiomyopathy Therapeutics surged due to the aging population and an increasing prevalence of cardiovascular diseases.
• The Italy Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 1.9%during the forecast period, with a market size of USD 39.33million in 2024.
• The Russia Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 1.5%during the forecast period, with a market size of USD 70.89million in 2024.
• The Spain Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 1.6%during the forecast period with a market size of USD 37.50million in 2024
• The Luxembourg Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 2.6%during the forecast period, with a market size of USD 14.18million in 2024.
• The Portugal Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 2.3%during the forecast period, with a market size of USD 9.60million in 2024.
• The Greece Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 2.8%during the forecast period, with a market size of USD 5.49million in 2024.
• The Rest of Europe's Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 1.2%during the forecast period, with a market size of USD 70.89million in 2024.

Asia Pacific Hypertrophic Cardiomyopathy Therapeutics

According to Cognitive Market Research, the global Hypertrophic Cardiomyopathy Therapeutics market size was estimated at USD 1524.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 350.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Hypertrophic Cardiomyopathy Therapeutics market size was valued at USD 157.79million in 2024 and is projected to grow at a CAGR of 5.5%during the forecast period. Hypertrophic Cardiomyopathy Therapeutics surged in China due to rising awareness, expanding healthcare access, and increasing investment in medical infrastructure.
• The Japan Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 4.5%during the forecast period, with a market size of USD 48.39 million in 2024.
• The India Hypertrophic Cardiomyopathy Therapeutics market had a market share of USD 42.08million in 2024 and is projected to grow at a CAGR of 7.8%during the forecast period. India's rising awareness, expanding healthcare access, and increasing investment in medical infrastructure.
• The South Korean Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 5.1%during the forecast period, with a market size of USD 35.06million in 2024.
• The Australian Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 5.7%during the forecast period, with a market size of USD 18.23million in 2024.
• The South East Asia Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 7.0%during the forecast period, with a market size of USD 24.19million in 2024.
• The Rest of Asia Pacific Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 5.8%during the forecast period, with a market size of USD 24.90million in 2024.

South America Hypertrophic Cardiomyopathy Therapeutics

According to Cognitive Market Research, the global Hypertrophic Cardiomyopathy Therapeutics market size was estimated at USD 1524.5 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 76.23 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Hypertrophic Cardiomyopathy Therapeutics market size was valued at USD 32.62million in 2024 and is projected to grow at a CAGR of 4.0%during the forecast period. Hypertrophic Cardiomyopathy Therapeutics flourished in Brazil due to increasing awareness of cardiovascular diseases and improving access to healthcare services in urban and semi-urban areas.
• Argentina's Hypertrophic Cardiomyopathy Therapeutics market had a market share of USD 12.81million in 2024 and is projected to grow at a CAGR of 4.3%during the forecast period. Argentina's increasing awareness of cardiovascular diseases and improving access to healthcare services in urban and semi-urban areas.
• Colombia Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 3.2%during the forecast period, with a market size of USD 6.78million in 2024.
• Peru Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 3.6%during the forecast period, with a market size of USD 6.25million in 2024.
• Chile Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 3.7%during the forecast period, with a market size of USD 5.49million in 2024.
• The Rest of Latin America's Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 2.5%during the forecast period, with a market size of USD 12.27million in 2024.

Middle East and Africa Hypertrophic Cardiomyopathy Therapeutics

According to Cognitive Market Research, the global Hypertrophic Cardiomyopathy Therapeutics market size was estimated at USD 1524.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 30.49 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031..

• The GCC Countries Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 4.5%during the forecast period, with a market size of USD 13.05million in 2024. Hypertrophic Cardiomyopathy Therapeutics sales flourish due to the growing awareness of cardiovascular disorders and increasing investments in healthcare infrastructure.
• The Egypt Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 4.0%during the forecast period, with a market size of USD 3.20million in 2024.
• The South Africa Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 4.7%during the forecast period, with a market size of USD 4.82million in 2024. Hypertrophic Cardiomyopathy Therapeutics sales flourished in South Africa due to growing awareness of cardiovascular disorders and increasing investments in healthcare infrastructure.
• The Turkey Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 3.2%during the forecast period, with a market size of USD 2.62million in 2024.
• The Nigeria Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 2.8% during the forecast period, with a market size of USD 3.20million in 2024.
• The Rest of the MEA Hypertrophic Cardiomyopathy Therapeutics market is projected to witness growth at a CAGR of 2.7%during the forecast period, with a market size of USD 3.60million in 2024.

Hypertrophic Cardiomyopathy Therapeutics Market Analysis

How are Segments Performing in the Global Hypertrophic Cardiomyopathy Therapeutics Market?

Hypertrophic Cardiomyopathy Therapeutics Market Disease Type Segment Analysis

According to Cognitive Market Research, Obstructive Hypertrophic Cardiomyopathy (HCM) segment holds a dominant position in the Hypertrophic Cardiomyopathy Therapeutics Market. This prominence is driven by the higher prevalence of obstructive HCM cases, which significantly impact cardiac function, requiring advanced therapeutic interventions. Increased patient awareness and improved diagnostic capabilities have fueled demand for targeted treatment options like beta-blockers, calcium channel blockers, and novel myosin inhibitors.

The Non-Obstructive Hypertrophic Cardiomyopathy (HCM) segment is poised to witness the fastest growth due to increasing awareness about its underdiagnosed nature. While less severe than its obstructive counterpart, non-obstructive HCM still poses risks of arrhythmias and sudden cardiac arrest. Advances in imaging technologies and genetic testing have improved detection rates, driving demand for therapeutics like antiarrhythmic drugs and anticoagulants. Additionally, ongoing research into the genetic basis of non-obstructive HCM and emerging treatment protocols have amplified growth opportunities.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Hypertrophic Cardiomyopathy Therapeutics Industry. Request a Free Sample PDF!

Hypertrophic Cardiomyopathy Therapeutics Market Drug Class Segment Analysis

According to Cognitive Market Research, the Beta Adrenergic Blocking Agents segment dominates the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market due to its proven efficacy in managing symptoms such as chest pain, shortness of breath, and arrhythmias associated with HCM. These drugs are widely regarded as first-line treatment options for both obstructive and non-obstructive HCM. The established clinical benefits, broad adoption by healthcare providers, and availability of multiple generic and branded options have solidified their leading position.

The Calcium Channel Blockers segment is projected to experience the fastest growth due to increasing recognition of their role in improving diastolic function and reducing left ventricular outflow tract obstruction. These agents are particularly effective for patients who do not respond adequately to beta blockers, expanding their application in HCM treatment. Enhanced awareness about their benefits, coupled with growing investments in research to refine their therapeutic potential, has accelerated demand.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Hypertrophic Cardiomyopathy Therapeutics End Users Outlook: Segment Analysis

Hypertrophic Cardiomyopathy Therapeutics Market End Users Segment Analysis

According to Cognitive Market Research, the Hospitals segment leads the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market due to its comprehensive capabilities in managing complex cardiovascular conditions. Hospitals are equipped with advanced diagnostic tools, such as echocardiography and cardiac MRI, ensuring accurate detection and personalized treatment. They also provide access to multidisciplinary care teams, including cardiologists, surgeons, and genetic counselors, enhancing treatment outcomes.

The Ambulatory Surgical Centers (ASCs) segment is expected to grow the fastest due to increasing patient preference for cost-effective and convenient care settings. ASCs specialize in providing minimally invasive procedures, such as septal myectomy, with shorter recovery times and reduced hospital stays. These centers are gaining traction as advancements in technology enable the safe performance of complex cardiac procedures outside traditional hospital settings.

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Academic and Research Organizations

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion